These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 17459416

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D.
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
    [Abstract] [Full Text] [Related]

  • 4. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chan J, Chen X, Fang Y, Wu F, He H, Ning Y.
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
    Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T.
    J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):608-10. PubMed ID: 20522869
    [Abstract] [Full Text] [Related]

  • 9. No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis.
    Goossens J, Bjerke M, Struyfs H, Niemantsverdriet E, Somers C, Van den Bossche T, Van Mossevelde S, De Vil B, Sieben A, Martin JJ, Cras P, Goeman J, De Deyn PP, Van Broeckhoven C, van der Zee J, Engelborghs S.
    Alzheimers Res Ther; 2017 Jul 14; 9(1):49. PubMed ID: 28709448
    [Abstract] [Full Text] [Related]

  • 10. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.
    Bousiges O, Bombois S, Schraen S, Wallon D, Quillard MM, Gabelle A, Lehmann S, Paquet C, Amar-Bouaziz E, Magnin E, Miguet-Alfonsi C, Delbeuck X, Lavaux T, Anthony P, Philippi N, Blanc F, ePLM network and collaborators.
    J Neurol Neurosurg Psychiatry; 2018 May 14; 89(5):467-475. PubMed ID: 29321140
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis.
    Slaets S, Van Acker F, Versijpt J, Hauth L, Goeman J, Martin JJ, De Deyn PP, Engelborghs S.
    Int J Geriatr Psychiatry; 2015 Aug 14; 30(8):864-9. PubMed ID: 25363642
    [Abstract] [Full Text] [Related]

  • 13. Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease.
    Hanyu H, Shimizu S, Hirao K, Kanetaka H, Iwamoto T, Chikamori T, Usui Y, Yamashina A, Koizumi K, Abe K.
    Eur J Nucl Med Mol Imaging; 2006 Mar 14; 33(3):248-53. PubMed ID: 16328506
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serum heart-fatty acid binding protein levels in patients with Lewy body disease.
    Wada-Isoe K, Imamura K, Kitamaya M, Kowa H, Nakashima K.
    J Neurol Sci; 2008 Mar 15; 266(1-2):20-4. PubMed ID: 17869272
    [Abstract] [Full Text] [Related]

  • 16. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, Neumann M, Steinacker P, Kretzschmar HA, Poser S, Trenkwalder C, Otto M.
    Dement Geriatr Cogn Disord; 2005 Mar 15; 19(2-3):164-70. PubMed ID: 15637452
    [Abstract] [Full Text] [Related]

  • 17. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF, Ha J, Chu LW.
    Psychogeriatrics; 2015 Dec 15; 15(4):235-41. PubMed ID: 25533477
    [Abstract] [Full Text] [Related]

  • 18. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielczyk B, Neubert K, Trenkwalder C, Otto M.
    Clin Chem Lab Med; 2006 Dec 15; 44(2):192-5. PubMed ID: 16475906
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
    van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, Bonanni L, Lemstra AW, European DLB consortium.
    J Alzheimers Dis; 2016 Aug 18; 54(1):287-95. PubMed ID: 27567832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.